Saptagir Laboratories enters into exclusive agreement with Jubilant Generics


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Saptagir Laboratories enters into exclusive agreement with Jubilant Generics
Another Indian company joins Remdesivir production

Hyderabad-based bulk drugs and intermediates firm Saptagir Laboratories, part of the Rs 900 crore Saptagir Group, has entered into an exclusive agreement with Jubilant Generics, a Jubilant Life Sciences company, to manufacture intermediates and bulk drugs for intravenous administered drug Remdesivir.

Announcing this strategic partnership, Shilpa Reddy, MD, Saptagir Laboratories said, “This partnership is timely and in line with our strategic growth plans for the company. Our foray into bulk drug manufacturing will open new revenue streams, backed by our extensive global customer base spanning over 50 countries with an array of products targeted at the fast-growing health and wellness segment.”

She told Telangana Today, “We are completing the validation for the intermediates and we will begin production soon. We will start production of bulk drugs from next month. The drug will be produced at our WHO Good Manufacturing Practices (GMP) certified sterile drug product manufacturing plant located near Medchal in Hyderabad. The plant was acquired in mid-2019 with an investment of Rs 75 crore.”

Mahesh Reddy, chairman, Saptagir Group said, “We have had several successes in product development in molecules that were previously only manufactured in China. This partnership meets the need of our multinational customers who approve India as a strong second source for products beyond China.”

Remdesivir is an experimental antiviral drug developed by Gilead Sciences, as a course of treatment for Covid-19. Gilead entered into a non-exclusive licensing agreement with Jubilant Life Sciences for distribution to 127 countries.

Following this, Jubilant Life Sciences through its subsidiary Jubilant Generics has entered an exclusive agreement with Saptagir Laboratories to manufacture Remdesivir. The market for Remdesivir according to Gilead Life Sciences, the innovator, is estimated to be $2.3 billion for this year.

Tags : #SaptagirLaboratories #JubiliantGenerics #GileadSciences #RemidesivirlatestNewsSep15 #JubiliantLifeSciences #latestPharmaNewsUpdateSep15

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026